Connect Biopharma Q2 2026: Rademikibart R&D Boost Drives Revenue Growth, Despite Net Loss
Connect Biopharma’s Q1‑Q2 2026 results show rising licensing revenue and Phase 2 R&D spending for rademikibart, hinting at future growth despite current losses.
- CONNECT BIOPHARMA HOLDINGS L
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- AI generated
3 minutes to read